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Introduction
Osteolytic bone diseases are characterized by bone destruction due to aberrant osteoclastogenesis. Various etiologies can cause osteolytic bone diseases, such as periprosthetic particles, infection and cancer [1] [2] [3] [4] . Breast cancer is the most common cancer that causes lytic bone destruction, leading to severe complications including severe bone pain, fracture and hypercalcemia [5, 6] .
Development of bone metastasis is a consequence of sophisticated interactions between cancer cells and diverse stromal cells, including osteoblasts, osteoclasts, and other stromal cells, in the bone microenvironment [1] . The tumor-stromal interaction plays a major role in boosting bone metastasis of cancer [2] . In osteolytic bone metastasis, cancer cells that colonize the bone microenvironment can directly communicate with pre-osteoclasts to induce osteoclastogenesis through cytokines such as intercellular adhesion molecule 1 (ICAM1) and chemokine (C-C motif) ligand 2 (CCL2) [3, 4] . Meanwhile, metastatic cancer cells also secrete signaling proteins, such as parathyroid hormone-related peptide (PTHrP), heparin binding epidermal growth factor-like growth factor (HB-EGF) and amphiregulin, which indirectly promote osteoclast differentiation by increasing osteoblasts-production of receptor activator for NF-κB ligand (RANKL) [5] [6] [7] . RANKL is the most important cytokine inducer of osteoclastogenesis, which binds to and activates its receptor (RANK) expressed on pre-osteoclasts. As a decoy receptor that prevents RANKL from binding to RANK, osteoprotegerin (OPG) is capable of inhibiting bone destruction and reducing skeletal tumor burden in animal models of breast cancer bone metastasis [8, 9] . The balance between RANKL and OPG regulates the course of osteolysis and break of this balance is discovered in many cancers, including breast cancer [10] .
Bone morphogenetic proteins (BMPs), members of the transforming growth factor β (TGF-β) superfamily, conduct their signals through receptors type 1 (BMPR1a and BMPR1b) and type 2 (BMPR2). Downstream of BMP signaling is transduced by either a canonical (Smad-dependent) or non-canonical (Smad-independent) pathway. Non-canonical BMP pathway is mediated by MAP kinases (MAPKs), including ERK, JNK, and p38 MAPK [11, 12] . In breast cancer, the role of BMP signaling is divergent. As critical downstream effectors of BMP signaling, BMP receptors played roles in both cancer promotion and cancer inhibition. One study showed that reduced expression of BMPR1b correlates with poor prognosis and increased proliferation of breast cancer cells [13] . Different studies showed contradictory roles of BMPR2 in breast cancer. One study showed that interference of BMPR2 promotes the metastasis of breast cancer [14] , while another study showed that interruption of BMPR2 inhibited the growth of breast cancer cells [15] . As for BMPR1a, the study at present showed that deletion of BMPR1a led to impaired onset and reduced metastasis of breast cancer [16] . In addition, it had been reported that high BMPR1a expression was correlated with poor relapse free survival in human breast cancers [17] . These studies indicated that BMPR1a might promote the development and progression of breast cancer. However, whether BMPR1a is involved in the bone metastasis of breast cancer is still unknown. We thus hypothesized that BMPR1a might play a positive role in the process of breast cancer metastasizing to bone.
In this study, we investigated the role of BMPR1a in breast cancer-induced osteolysis and explored the underlying mechanism of BMPR1a-regulated tumor-stromal interaction of bone metastasis.
Materials and Methods
Cells and chemical treatments
Human breast cancer MDA-MB-231-luc and MCF-7 cells were cultivated in DMEM (HyClone) with 10% (v/v) FBS (ExCell Bio), 100 IU/mL penicillin, and 100 mg/mL streptomycin (HyClone) at 37 °C. Murine RAW264.7 cells were cultivated in α-MEM (HyClone) with 10% (v/v) FBS (ExCell Bio), 100 IU/mL penicillin, and 100 mg/mL streptomycin (HyClone) at 37 °C. SB203580 (Merck Millipore), U0126 (Merck Millipore) 
Adenoviral vector production and transduction
Recombinant adenovirus vector containing shRNA targeted against BMPR1a or siRNA targeted against p38 gene (sip38) was constructed using modified AdEasy system as previously described [18] . MDA-MB-231-luc cells or MCF-7 cells were transduced with three different adenoviral BMPR1a shRNAs, shRNA-1, shRNA-2 or shRNA-3, respectively (Table  1) . With the highest efficacy in knockdown of BMPR1a in the two cell lines, shRNA-2 was selected for the subsequent experiments. Cells without transduction, cells transduced with shRNA-2 or a scrambled shRNA were named as CTL, shBMPR1a or shCTL cells for brevity, respectively. Cells transduced with sip38 or a scrambled siRNA were named as sip38 or siCTL cells for brevity, respectively.
Intratibial implantation
Four-week-old female BALB/c nude mice were purchased from Animal Center of Chongqing Medical University. Animals were raised in a temperature-constant environment (24 ± 1°C; humidity ≥40%) on a 12-hour light-dark cycle until they were six weeks old, given free approach to water and food. All procedures referring to animals were in keeping with the protocol approved by the Animal Ethics Committee of Chongqing Medical University (Chongqing, China). Six-week-old nude mice were intratibially injected with MDA-MB-231-luc cells as previously described [19] . CTL, shCTL or shBMPR1a MDA-MB-231-luc cells were harvested, resuspended in serum-free DMEM and injected into the left tibia of nude mice. At 5 weeks post-injection, the mice received intraperitoneal administration of D-Luciferin (150 mg/kg in PBS; Yeasen) and were then monitored by whole-body in vivo bioluminescence imaging (PerkinElmer) to measure the progression of skeletal tumor burden. Mice were finally euthanized by anesthetic overdose at 6 weeks postinjection. The metastatic legs were dissected for microCT analysis, embedded in paraffin after decalcification and finally sliced into 5-μm sections.
Bone histology and histomorphometry
Bone histologic and histomorphometric analysis of bone tissue sections were conducted with hematoxylin and eosin (H&E) staining. For histomorphometric measurement of the tumor burden in bone, tumor area and total area were determined as previously described [20] . In addition, osteoclasts at the tumor-bone interface in bone sections were detected by tartrate resistant acid phosphatase (TRAP) staining using Acid Phosphatase Leukocyte (TRAP) Kit (Sigma).
RNA isolation and RT-PCR analysis
Total RNA was isolated by Trizol reagent (Ambion), followed by chloroform extraction and isopropyl alcohol precipitation. RNA was quantified by UV spectrophotometry and was reverse transcribed using Revert Aid First Strand cDNA Synthesis Kit (Thermo). RT-PCR analysis was carried out using KAPA SYBR FAST qPCR Kit (KAPA BIOSYSTEMS) following the manufacturer's instructions (Table 2 : List of primers).
Protein extraction and Western blotting
Cell lysates in RIPA buffer were centrifuged at 12, 000 × g for 20 min at 4 °C, and the supernatants were collected for the examination of protein concentration by BCA assay (BCA protein assay kit; Beyotime). Proteins (50 μg) were electrophoresed on SDS-polyacrylamide gels at 100V for 90 minutes and then transferred onto nitrocellulose membranes (Millipore) at 400mA for 90 minutes. Membranes were blocked with 5% BSA in TBS-T (TBS with 0.05% Tween 20) and incubated with primary antibodies against BMPR1a (ab38560, 1:1, 000 dilution, Abcam), Cathepsin-K (ARG20173, 1:1, 000 dilution, Arigo), TRAP (SAB3500943, 1 mg/mL, Sigma), RANK (4845, 1:1, 000 dilution, Cell Signaling Technology), RANKL (SAB4503430, 1 mg/mL, Sigma), OPG (O1139, 1 mg/mL, Sigma), p38 (8690, 1:1, 000 dilution, Cell Signaling Technology), 
Immunofluorescence
Immunofluorescence staining was performed on 5-μm thick paraffin sections of metastatic legs. Sections were deparaffinized and rehydrated in graded ethanol and permeabilized in 0.01M sodium citrate buffer by heating at sub-boiling temperature for 15 minutes and then allowed to cool down at room temperature for 45 minutes. The sections were then washed in PBS and blocked with 5% normal goat serum for 1 hour. Primary antibodies against BMPR1a (ab38560, 1:200 dilution, Abcam) or Cathepsin-K (ARG20173, 1:200 dilution, Arigo) were incubated at 4 °C overnight with subsequent incubation at room temperature for 45 minutes. After being washed, sections were further incubated for 1 hour with a secondary antibody coupled to DyLight 488 (A23320, 1:1, 000 dilution, Abbkine) or DyLight 549 (A23220, 1:1, 000 dilution, Abbkine) and were then stained with DAPI for 30 minutes followed by another wash. Coverslips were finally mounted in neutral balsam.
Immunohistochemistry
Bone sections were deparaffinized, treated with 0.01M sodium citrate buffer by heating at sub-boiling temperature for 15 minutes and processed for immunohistochemical staining using a BMPR1a antibody (ab38560, 1:200 dilution, Abcam).
Osteoclastogenesis assay and conditioned media
Conditioned media were collected from CTL, shCTL or shBMPR1a MDA-MB-231-luc cells or MCF-7 cells as previously described [6] . Bone marrow mononuclear cells (BMMCs) from 6-week-old BALB/c mice were harvested as previously described [4] . Conditioned media were mixed with fresh serum-containing α-MEM medium (1:1, v/v). In order to induce osteoclasts differentiation, Primary pre-osteoclast BMMCs were treated with the mixed media supplemented with 50 ng/ml RANKL as previously described [21] every other day for 9 days. Murine pre-osteoclast RAW264.7 cells were also treated with the mixed medium accompanied with RANKL (50ng/ml) every day for 5 days. Mature osteoclasts were stained by Acid Phosphatase Leukocyte (TRAP) Kit (Sigma) and calculated under a microscope according to the number of nuclei (more than three nuclei).
ELISA
Conditioned media of CTL, shCTL or shBMPR1a breast cancer cells were collected and the level of RANKL in the conditioned media was measured by ELISA, according to the manufacturer's instructions (CUSABIO).
MicroCT analysis
Tibias dissected from tumor-bearing mice were scanned by vivaCT 40 (Scanco Medical AG). Computed tomographic slices were obtained using an X-ray tube with 70 kVp potential, after which they were reconstructed at a voxel size of 10 μm. The bone tissue was segmented from soft tissue according to a global thresholding procedure [22] . The 2D slices and 3D images were reconstructed by Mimics software (Materialise).
Statistical analysis
Statistical analyses among groups were performed using Student's t test for bivariate analyses, and all experimental data were presented as mean and standard error (SD) of the mean. A probability (p) value of less than 0.05 was considered statistically significant. Statistical analyses were conducted using GraphPad Prism 7.0.
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Results
BMPR1a is prominently expressed in metastatic breast cancer cells
To explore the role of BMPR1a in tumor-stromal interaction in bone metastasis, human breast cancer MDA-MB-231-luc cells were injected intratibially into nude mice to construct a breast cancer bone metastasis model [23] . Immunofluorescent analysis for BMPR1a of tumor-bearing bone sections obtained from different metastatic mice demonstrated a stronger staining of BMPR1a of breast cancer cells at the tumor-bone interface, compared with cancer cells distant from the interface (Fig. 1A) . Furthermore, immunohistochemical analysis of sections also showed that the expression level of BMPR1a of MDA-MB-231-luc cells was significantly higher at the tumor-bone interface compared with that of breast cancer cells distant from the interface (Fig. 1B and 1C) . These results indicated that BMPR1a might be crucial in the interaction between metastatic cancer cells and bone microenvironment.
Knockdown of BMPR1a disrupts tumor growth in vivo
Three different shRNAs targeted against human BMPR1a gene, shRNA-1, shRNA-2 or shRNA-3, were then transduced into MDA-MB-231-luc cells, respectively. Although three shRNAs demonstrated all above 90% transduction efficiencies (data not shown) and similar knockdown efficiencies of expression of BMPR1a at mRNA level ( Fig. 2A) , shRNA-2 was selected for the following experiment due to its highest knockdown efficiency of BMPR1a protein compared with shRNA-1 or shRNA-3 ( Fig. 2B and 2C) .
The nude mice were divided into three groups and were intratibially injected with MDA-MB-231-luc cells (control group, CTL group), cells transduced with BMPR1a shRNA-2 (shBMPR1a group) or cells transduced with a scrambled shRNA (shCTL group), respectively. Bioluminescence imaging (BLI) at 5 weeks post-injection showed that the tumor growth was inhibited in shBMPR1a group, compared with that of shCTL or CTL group (Fig. 2D and  2E ). In accordance with BLI result, tumor-bearing legs of shBMPR1a mice dissected at 6 weeks post-injection were much smaller in size than those of shCTL or CTL mice (Fig. 2F) . Morphological measurements of metastatic legs of shBMPR1a mice showed significant decreases in tumor weight and tumor size compared with those of CTL or shCTL mice ( Fig.  2G and 2H ). These results demonstrated that knockdown of BMPR1a of breast cancer cells suppressed the growth of metastatic tumor. 
Knockdown of BMPR1a decreases breast cancerinduced lytic bone lesion To explore the influence of BMPR1a-knockdown of breast cancer cells on cancer-induced bone destruction, we examined the metastatic legs by microCT. Compared with CTL or shCTL mice, bone destruction in shBMPR1a mice was significantly reduced as shown by microCT two-dimensional (2D) images (Fig. 3A) . Bone volume of metastatic leg in shBMPR1a group was significantly increased compared with that of control groups (Fig. 3B) . The decrease of bone destruction in shBMR1a group is better displayed in three-dimensional (3D) reconstructed images (Fig.  3C ). In accordance with radiological data, H&E staining of sections of the metastatic legs from shBMPR1a mice showed a significant reduction in bone destruction and a significant decrease in tumor burden (Fig. 4A and 4B ) compared with control groups. Meanwhile, TRAP staining of sections of shBMPR1a mice also demonstrated an apparent decrease of TRAPpositive (TRAP+) area at the tumor-bone interface than that of CTL or shCTL group (Fig.   Fig. 2 4A and 4C), which indicated that differentiation of osteoclasts at the interface was significantly decreased. Furthermore, immunofluorescent staining of sections of metastatic legs showed a decrease in the expression of Cathepsin-K, a key protease for bone destruction [24] , at the tumor-bone interface in shBMPR1a mice compared with CTL or shCTL mice (Fig. 5) . These results indicated that knockdown of BMPR1a of breast cancer cells inhibited osteoclastogenesis at the bone-tumor interface and suppressed cancer-induced bone destruction in vivo.
Knockdown of BMPR1a impairs cancer cell-induced osteoclastogenesis
In order to investigate the impact of tumor BMPR1a on osteoclastogenesis in vitro, conditioned media from MDA-MB-231-luc cells and MCF-7 cells were collected to induce the differentiation of osteoclasts. MDA-MB-231-luc cells or MCF-7 cells were transduced with the shRNA-1, shRNA-2 or shRNA-3. Western blotting analysis showed that shRNA-2 demonstrated the highest knockdown efficiency of BMPR1a in both cells among the three shRNAs (Fig. 2B) . 
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Murine bone marrow mononuclear cells (BMMCs) were treated with conditioned media of MDA-MB-231-luc cells or MCF-7 cells in combination with RANKL, a crucial cytokine inducer of osteoclastogenesis [8] . Conditioned media of shBMPR1a MDA-MB-231-luc cells significantly decreased the formation of TRAP+ multinucleated osteoclasts (more than three nuclei) compared with shCTL or CTL media ( Fig. 6A and 6B) . Meanwhile, conditioned media of shBMPR1aMCF-7 cells led to a similar reduction of TRAP+ osteoclasts compared with shCTL or CTL media ( Fig. 6C and 6D) . Besides, Western blotting analyses showed that the expressions of characteristic biomarkers of mature osteoclasts, including Cathepsin-K, TRAP and receptor activator for NF-κB (RANK), were decreased at protein level in BMMCs treated with shBMPR1a media of MDA-MB-231-luc cells compared with those of control media (data not shown). Similar decreases of the characteristic proteins levels were also found in BMMCs which were treated with media of MCF-7 cells (data not shown). In summary, these results manifested that knockdown of BMPR1a of cancer cells suppressed breast cancer-induced osteoclastogenesis in vitro.
Knockdown of BMPR1a of breast cancer cells suppresses RANKL through p38 pathway
Previous studies had shown that the balance between RANKL and its decoy receptor OPG could regulate the process of bone resorption [10] . To explore whether RANKL and OPG were involved in the osteoclastogenesis regulated by tumor BMPR1a, we examined the protein expressions of RANKL and OPG of breast cancer cells and found a reduction of RANKL and an increase of OPG in the shBMPR1a MDA-MB-231-luc cells compared with those of control cells (Fig. 7A) . There was also a reduction of RANKL and an increase of OPG at protein levels in shBMPR1a MCF-7 cells compared with those of control cells (Fig. 7B) . These results showed a sharp decrease in the ratio of RANKL to OPG (RANKL/OPG) in shBMPR1a cells compared with those of control cells (Fig. 7A and 7B ). In addition, levels of soluble RANKL in the conditioned media of shBMPR1a MDA-MB-231-luc or MCF-7 cells were decreased compared with respective control cells as measured by ELISA assay (Fig. 7C and  7D ). These results indicated that knockdown of BMPR1a impaired the expression of RANKL in breast cancer cells.
To further investigate the mechanisms by which BMPR1a-knockdown impaired the expression of RANKL, we focused on the MAPK pathways. Western blotting analyses of phosphorylated p38, Erk1/2 and JNK showed a decrease of p-p38 and p-Erk1/2 in shBMPR1a MDA-MB-231-luc cells compared with those of control cells while there was no significant change in p-JNK (Fig. 7E) . Similarly, protein levels of p-p38 and p-Erk1/2 were also decreased and the level of p-JNK was not apparently changed in shBMPR1a MCF-7 cells compared with those of control cells (Fig. 7F) . Here, we then asked whether there was a possible link between noncanonical BMP signaling and RANKL in the breast cancer cells. Therefore, MDA-MB-231-luc cells and MCF-7 cells were treated with BMP signaling inhibitors SB203580 (p38 inhibitor), 
U0126 (ERK1/2 inhibitor) or SP600125
(JNK inhibitor). SB203580 and U0126 suppressed RANKL protein expression and increased OPG protein expression in MDA-MB-231-luc cells, while SP600125 didn't change the expression of RANKL or OPG. Meanwhile, similar changes of RANKL and OPG were also found in MCF-7 cells. In addition, the reduction of RANKL expression caused by p38 inhibitor was apparently higher than that caused by Erk1/2 inhibitor, which indicated that p38 might be more important in the regulation of RANKL expression in breast cancer cells. (Fig. 7G and 7H) .
Knockdown of p38 of breast cancer cells suppresses cancer-induced osteoclastogenesis in vivo and in vitro
To further explore whether p38 influences breast cancer-induced bone destruction, MDA-MB-231-luc cells and MCF-7 cells were transduced with adenovirus-mediated small interfering RNA (siRNA) targeted against human p38 gene (sip38 group) or a scrambled siRNA (siCTL group). Murine RAW264.7 cells were treated with the conditioned media of siRNA-transduced MDA-MB-231-luc cells or MCF-7 cells. Conditioned media of sip38 MDA-MB-231-luc cells decreased the number of TRAP+ osteoclasts in RAW264.7 cells compared with that of conditioned media of siCTL cells (Fig. 8A) . Similar reduction of osteoclast differentiation was also found in RAW264.7 cells treated with conditioned media of MCF-7 cells (Fig. 8B) . Meanwhile, siRNA-transduced breast cancer cells were injected into the tibia of nude mice. In mice that were injected with MDA-MB-231-luc cells, TRAP staining of sections of metastatic legs showed that TRAP+ area was decreased in sip38 group than that of siCTL group (Fig. 8C) . In mice injected with MCF-7 cells, there was also a reduction of TRAP+ area in sections of sip38 group than those of siCTL group (Fig. 8D) . These results further demonstrated that p38-knockdown of breast cancer cells suppresses cancer-induced 
Discussion
Breast cancer is the most common malignancy in women worldwide [25] . Bone metastasis is a frequent occurrence in advanced breast cancers [2] . Tumor-stromal interaction plays a major role in promoting osteolytic metastasis of breast cancer, therefore understanding the molecular mechanism of tumor-stromal interactions is crucial for the treatment of bone metastasis [1, 26] . In this study, we aimed to explore the role of BMPR1a of breast cancer cells in the interaction between metastatic cancer cells and osteoclast precursors in bone metastasis. Our study found that BMPR1a-knockdown of breast cancer cells inhibited cancer-induced osteoclastogenesis by suppressing RANKL expression of cancer cells through p38 pathway.
In osteolytic metastasis, the tumor-bone (TB) interface mainly consists of cancer cells and osteoclasts [27, 28] . The bidirectional tumor-stromal interaction often takes place at the TB interface where tumor cell-derived cytokines stimulate osteoclast differentiation, resulting in degradation of the bone matrix and the release of bone-derived cytokines that further promote tumor growth [1, 26] . The activated factors at the TB interface implied the involvement of them in the tumor-stromal interaction [27, 29, 30] . We utilized a model of bone metastasis which was confirmed as a fine model to replicate the tumor-induced changes in bone microenvironment [31] . By performing immunohistochemical and immunofluorescent analyses of sections of bone metastasis, we found the expression of BMPR1a of breast cancer cells at the TB interface was higher than that of cancer cells distant from the interface. These results suggested an active participation of BMPR1a in the tumor-stromal interaction, or rather, in cancer cells-preosteoclasts interaction of bone metastasis. Subsequently, we observed decreased cancer-induced osteolysis in mice of shBMPR1a group than those of control groups, a consequence of reduced osteoclast differentiation at the TB interface. As the sole cell type in human that is responsible for bone degradation, osteoclasts have been the highlight in the research of tumor-stromal interactions in bone metastasis [24] . Meanwhile, our immunofluorescent analysis showed that the level of Cathepsin-K at the TB interface was decreased in shBMPR1a group compared with that of control groups (Fig. 5) . Lynch et al. showed that gene expression of Cathepsin-K, an osteoclast-produced enzyme known to contribute to bone resorption, was elevated at the TB interface of prostate cancer bone metastasis [27] . These results suggested that differentiation and activation of osteoclasts at the [2, 32] . Among cytokines that demonstrate multi-effect in spurring excessive osteoclast activity and promoting osteolytic metastasis, RANKL is the most prominent cytokine inducer of osteoclastogenesis [1, 33, 34] . RANKL binding to its receptor (RANK) expressed on the osteoclast precursors and metastatic cells activates NF-κB signaling, resulting in both the transcription of crucial osteoclastogenic cytokines and elevated breast cancer cell migration selectively to bone [2] . Our results showed a reduction in the level of RANKL and an elevation in OPG in shBMPR1a cancer cells compared with those of control groups. Furthermore, the level of soluble RANKL was also decreased in supernatants of shBMPR1a breast cancer cells by ELISA assay compared with that of control groups (Fig. 7C and 7D) . These results suggested that knockdown of BMPR1a of breast cancer cells inhibited both the production and the secretion of RANKL. As the decoy receptor of RNAKL, OPG antagonized the activity of RANKL in normal bone homeostasis [2, 35] . Morony et al. found that exogenous addition of OPG resulted in a significant reduction of osteolytic tumor growth [36] . Because the balance between RANKL and OPG regulates the process of bone resorption, the ratio of RANKL to OPG (RANKL/OPG) was thus considered as a functional indicator of osteoclast differentiation [10, 37, 38] . Our data found a decreased ratio of RANKL/OPG in shBMPR1a breast cancer cells, which might account for the impaired osteoclastogenesis caused by shBMPR1a cancer cells.
BMP signaling was transduced by either a canonical Smad-dependent or non-canonical MAPK dependent (p38 MAPK, ERK1/2, and JNK) pathway [28, 39] . Katsuno et al. found that bone morphogenetic protein signaling promoted the bone metastasis of breast cancer cells through Smad pathway [40] . However, the role of non-canonical pathway in bone metastasis of breast cancer is largely unknown. Our results demonstrated that phosphorylation of p38 and Erk1/2 (p-p38 and p-Erk1/2) were notably decreased in shBMPR1a MDA-MB-231-luc or MCF-7 cells compared with those in control groups. Furthermore, p38 inhibitor (SB203580) or Erk1/2 inhibitor (U0126) decreased the protein level of RANKL in breast cancers compared with cells without treatment. In contrast, JNK inhibitor didn't alter the level of RNAKL and therefore JNK was not explored further. The reduction of RANKL expression caused by p38 inhibitor was apparently higher than that caused by Erk1/2 inhibitor. Although the involvement of Erk1/2 might not be surely excluded, under the present indications the p38 pathway was further examined in regard to the regulation of RANKL. We then interrupted p38 of breast cancer cells by siRNAs and found that p38-knockdown of breast cancer cells inhibited cancer-induced osteoclastogenesis in vitro and in vivo. Our results found that the reduced expression of RANKL in BMPR1a-knockdown breast cancer cells was probably mediated by p38 pathway, but the underlying mechanism needed further exploration.
In conclusion, our discoveries collectively demonstrate that knockdown of BMPR1a of breast cancer cells suppresses the expression of RANKL through p38 pathway, which attenuates cancer-induced bone destruction in vivo and cancer-induced osteoclastogenesis in vitro. Our results suggest that BMPR1a might be a potential target for the treatment of cancer-induced osteolytic metastasis.
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